Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800935 | 0.81 | MAPT (0.56) | MAPTSMN1; SMN2MEN1KMT2AHDAC4 | |
| SCHEMBL10195746 | 0.77 | MEN1 (0.69) | MAPTSMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL2747321 | 0.76 | MAPT (0.68) | MAPTSMN1; SMN2MEN1KMT2AHDAC4 | |
| SCHEMBL2376378 | 0.76 | SMN1; SMN2 (0.71) | MAPTSMN1; SMN2MEN1KMT2AHSD11B1 | |
| SCHEMBL14261406 | 0.76 | MAPT (0.68) | MAPTSMN1; SMN2MEN1KMT2AHDAC4 | |
| SCHEMBL4548020 | 0.76 | POLB (0.69) | MAPTSMN1; SMN2MEN1KMT2AHDAC4 | |
| SCHEMBL15134817 | 0.76 | MAPT (0.68) | MAPTSMN1; SMN2MEN1KMT2AHSD11B1 | |
| SCHEMBL6707299 | 0.76 | HSD11B1 (0.71) | MAPTSMN1; SMN2MEN1KMT2AHSD11B1 | |
| SCHEMBL2747017 | 0.74 | KCNJ1 (0.73) | MAPTSMN1; SMN2MEN1KMT2AKCNJ1 | |
| SCHEMBL15317673 | 0.74 | MAPT (0.64) | MAPTSMN1; SMN2MEN1KMT2AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2064212-A1 | PYRROLO ISOQUINOLINES AS KINASE INHIBITORS | Novartis AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008025512-A1 | PYRROLO ISOQUINOLINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069360-A1 | ORGANIC COMPOUNDS | SLCO1B3, CYP3A7, SLCO1B1 | MAPT 2247/4885SMN1; SMN2 1771/4885MEN1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.